Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

Two studies used weight-based dosing (pembrolizumab <2 mg/kg and nivolumab <2.15 mg/kg), showing similar OS to standard dosing in non–small cell lung cancer (NSCLC) and renal cell carcinoma, ...

(Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented increase in overall and melanoma-specific survival, as compared with ipilimumab alone. We should be wary ...

Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.

Trisha Wise-Draper, MD, PhD, discusses anticipated data on head and neck cancers and their potential impact on the field.

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...

The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

in combination nivolumab or pembrolizumab for the treatment of patients with lung metastases from NSCLC or other solid tumors to be presented by principal investigator Dr. Colette Shen at 8:00 AM EDT ...